METTL16、MAT2A在胃癌组织中的表达及其与胃癌患者临床病理参数、预后的关系

Expression of METTL16 and MAT2A in gastric cancer and their correlation with clinicopathological parameters and prognosis

目的探讨甲基转移酶样蛋白16(METTL16)和甲硫氨酸腺苷转移酶2A(MAT2A)在胃癌中的表达及两者与胃癌患者临床病理参数、预后的关系。方法将2018年3月至2019年3月于该院诊治的92例胃癌患者纳入研究。采用免疫组化的方法检测癌及癌旁组织中METTL16和MAT2A的表达情况。采用Spearman秩相关分析METTL16和MAT2A表达的相关性。比较不同临床病理特征胃癌患者METTL16、MAT2A表达差异。采用Kaplan-Meier生存分析来研究METTL16、MAT2A表达对胃癌患者生存预后的影响。单因素和多因素COX回归分析影响胃癌患者生存预后的因素。结果胃癌组织中METTL16、MAT2A表达阳性率分别为73.91%(68/92)、71.74%(66/92),明显高于癌旁组织[26.09%(24/92)、25.00%(23/92)],差异均有统计学意义(χ^(2)=42.087、40.238,P<0.001)。胃癌组织中METTL16与MAT2A蛋白表达呈正相关(r=0.769,P<0.001)。不同肿瘤TNM分期及淋巴结转移情况的患者癌组织中METTL16、MAT2A表达阳性率比较,差异均有统计学意义(P<0.05)。METTL16阳性组及阴性组3年总体生存率分别为63.24%(43/68)、87.50%(21/24),平均生存时间分别为(30.26±2.33)、(33.95±2.51)个月。METTL16阳性组的生存预后差于METTL16阴性组(Log-Rankχ^(2)=3.913,P=0.011)。MAT2A阳性组及阴性组3年总体生存率分别为60.61%(40/66)、92.31%(24/26),平均生存时间分别为(29.75±2.24)、(34.87±2.63)个月。MAT2A阳性组的生存预后差于阴性组(Log-Rankχ^(2)=4.335,P=0.002)。肿瘤TNM分期Ⅲ期、伴淋巴结转移、METTL16阳性、MAT2A阳性是影响胃癌预后的独立危险因素。结论胃癌组织中METTL16、MAT2A表达升高,两者表达与肿瘤分期及淋巴结转移有关,是影响胃癌患者生存预后的独立因素。

Objective To investigate the expression of methyltransferase like protein 16(METTL16)and methionine adenosyltransferase 2A(MAT2A)in gastric cancer and their correlation with clinicopathological parameters and prognosis.Methods A total of 92 patients with gastric cancer diagnosed and treated in the hospital from March 2018 to March 2019 were enrolled in the study.The expression of METTL16 and MAT2A in cancer and adjacent tissues was detected by immunohistochemistry.Spearman rank correlation analysis was used to analyze the correlation between METTL16 and MAT2A expression.The expression of METTL16 and MAT2A in patients with different clinicopathological characteristics were compared.Kaplan-Meier survival analysis was used to analyze the influence of METTL16 and MAT2A expression on survival prognosis.Univariate and multivariate COX regression analysis were used to analyze factors affecting survival prognosis of gastric cancer patients.Results The positive rates of METTL16 and MAT2A expression in gastric cancer tissues were 73.91%(68/92)and 71.74%(66/92),respectively,which were significantly higher than those in the paracancerous tissues[26.09%(24/92),25.00%(23/92)],the differences were statistically significant(χ^(2)=42.087,40.238,P<0.001).METTL16 was positively correlated with MAT2A protein in gastric cancer(r=0.769,P<0.001).The positive rates of METTL16 and MAT2A expression in cancer tissues of patients with different tumor stages and lymph node metastasis were statistically significant(P<0.05).The overall 3-year survival rates of METTL16 positive and negative groups were 63.24%(43/68)and 87.50%(21/24),respectively.The average survival time was(30.26±2.33)and(33.95±2.51)months,respectively.The survival prognosis of the METTL16 positive group was significantly poorer than than that of METTL16 negative group(Log-Rankχ^(2)=3.913,P=0.011).The overall 3-year survival rates of the MAT2A positive group and the MAT2A negative group were 60.61%(40/66)and 92.31%(24/26),respectively,and the average survival time was(29.75±2.24)and(34.87±2.63)months,respectively.The survival prognosis of the MAT2A positive group was significantly poorer than that of the negative group(Log-Rankχ^(2)=4.335,P=0.002).Tumor stageⅢ,lymph node metastasis,METTL16 positive,MAT2A positive were independent risk factors affecting the prognosis of gastric cancer.Conclusion The expression of METTL16 and MAT2A in gastric cancer is increased.Both of them are related to tumor stage and lymph node metastasis and are independent factors affecting the survival and prognosis of gastric cancer patients.